Dear reviewer:
Thanks for your efforts and comments. We have revised the manuscript accordingly. Please see our point to point responses below.

Comments and Suggestions for Authors
This small study reports on the expression of a cell marker in patients with established psoriatic arthritis compared to healthy controls. The authors claim that this could serve as an early biomarker for the disease. Unfortunately, they can’t make this claim from the data they present. We would need to see other cohorts – people with psoriasis without musculoskeletal symptoms, early untreated psoriatic arthritis, different subgroups of psoriatic arthritis, and patients with other inflammatory diseases especially rheumatoid arthritis. The best they can claim is that the biomarker is present in established disease (v HC) and it diminishes after successful treatment. Please also note that CASPAR criteria are for classification, not diagnosis.
Response:
Thanks for the useful comments. The title has been replaced to avoid the use of diagnostic biomarker. In addition, patients with psoriasis without arthritis (n=17), two more small groups from RA and AS (n=3 and 3, respectively) were used to compare their expression levels of miR-146a-5p in PsA and in NCs. The title has been replaced as ‘’MiR-146a-5p expression in peripheral CD14+ monocytes from patients with psoriatic arthritis induces osteoclast activation, bone resorption, and correlates with clinical efficacy”. We also revised the manuscript in the section of discussion and conclusion to avoid the use of disease biomarkers for miR-146a-5p.

We hope that the revised manuscript in its current form is of general
interest for the readers and is appropriate for publication in *Journal of Clinical Medicine*.

With best regards,

Chih-Hung Lee, MD, PhD.
Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Address: Ta-Pei Road 123, Niao-Sung district, Kaohsiung 83301, Taiwan
Telephone: +886-7-7317123 ext 2299
Email: dermlee@gmail.com